TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07538583: Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Sponsor: Quoin Pharmaceuticals · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,539,152

Rescue Site Savings

+$1,012,600

Unlock Full NCT07538583 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07538583 Rescue Dossier →